Loading…
JBT Marel Corporation
$5.8B
Market Cap
48.0
P/E
1.92
PEG
4.7%
ROCE
-1.7%
ROE
0.44
D/E
4.9%
OPM
-32.0%
% from 52W High
26
α RS
🔍 JBTM is showing a notable setup because Sector RRG has Industrials in the Improving quadrant with the trail still strengthening and an ECS of 67.2 last quarter. Net: Partial signal stack, not a recommendation. ? RRG ECS
Sources
Industrials in Improving quadrant · ECS 67.2
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for JBTM including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

JBT Marel Corporation provides technology solutions to food and beverage industry in the United States, Canada, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company operates through Protein Solutions and Prepared Food and Beverage Solutions. It offers value-added processing that includes equipment, solutions, software and services, stunning, slaughtering, scalding/dehairing, chilling, mixing/grinding, separation, injecting, blending, marinating, tumbling, flattening, forming, portioning, coating, cooking, frying, freezing, extracting, pasteurizing, sterilizing, concentrating, high pressure processing, weighing, inspecting, filling, closing, sealing, end of line material handling, labeling, and packaging solutions to the food, beverage, and health market. The company also provides automated guided vehicle systems for material handling requirements in the automotive manufacturing, warehouse, and medical facilities. It serves poultry, beef, pork, seafood, ready-to-eat meals, fruits, vegetables, plant-based meat alternatives, dairy, bakery, pet foods, soups, sauces, juices, and aqua feed industries. The company markets and sells its products and solutions through direct sales force, independent distributors, sales representatives, and technical service teams. The company was formerly known as John Bean Technologies Corporation and changed its name to JBT Marel Corporation in January 2025. JBT Marel Corporation was incorporated in 1994 and is headquartered in Chicago, Illinois.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding JBTM
View All Superinvestors →
Manager Shares Value % of Fund Period
Steve Cohen Point72 Asset Management 218.7K $28.0M 0.04% Mar 2026
Jim Simons Renaissance Technologies LLC 41.5K $5.3M 0.01% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →
📊 MIXED Q1 2026: Orders exceed $1B; revenue $936M; EBITDA margin 15.2%; leverage 2.6x
Revenue & Profitability
Consolidated revenue for Q1 2026 was $936 million, up approximately 10% year-over-year. Adjusted EBITDA was $142 million, a 27% improvement, with margin expanding 210 basis points to 15.2%. Free cash flow was $100 million, representing 70% conversion of adjusted EBITDA. Leverage ratio improved to 2.6x at quarter-end.
Outlook
Management remains confident in the full-year 2026 guidance, reflecting revenue growth of 6% at the midpoint, adjusted EBITDA margin expansion of 145 basis points, and adjusted EPS improvement of 29%. Second-quarter 2026 guidance calls for revenue of $975 million to $1 billion and adjusted EBITDA margins of 17% to 17.5%. Poultry demand globally is robust and expected to continue, while prepared food markets show signs of recovery.
Growth Drivers
Key growth drivers include robust global poultry demand, with Europe strong, North America earlier in the cycle, and South America potentially having a record year. The North American line speed opportunity (moving from 140 to 175 birds per minute) is a multi-year tailwind. Cross-selling legacy JBT and Marel solutions is capturing synergistic orders. Prepared Food and Beverage segment saw double-digit order growth in Q1, signaling recovery in CPG and QSR end markets.
Balance Sheet & CapEx
Not discussed in this earnings call.
Margins
Consolidated adjusted EBITDA margin was 15.2% in Q1 2026, up 210 basis points year-over-year. Protein Solutions margin improved by over 500 basis points to 21.7%, driven by poultry volume leverage and Marel Meat/Fish synergies. Prepared Food and Beverage margin declined 170 basis points to 14.7% due to tariffs, volume decline, and Warehouse Automation underperformance. Sequential margin improvement is expected through the year, with Q2 company-wide margins guided at 17% to 17.5%.
Key Risks
Management flagged tariff headwinds expected to create a 25 to 50 basis point margin impact after mitigation, with IEEPA tariff elimination offset by Section 122 and 232 increases. The Middle East conflict has less than 5% revenue exposure but causes logistics and energy inflation, which customers appear able to pass through. Warehouse Automation business faced demand and project headwinds, but actions are underway to address margins.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-08-04
Orders rose 10% year-over-year, with strong Protein Solutions growth and robust backlog supporting 2026 guidance. Margin improvement is expected in H2 as footprint optimization and operational initiatives progress, while inflation and logistics remain key risks.
Q1 2026 Q1 2026 2026-05-05
Orders exceeded $1 billion for the second straight quarter, with strong poultry demand and margin expansion. Revenue grew 10% year-over-year, and guidance for 2026 is maintained, targeting further margin and EPS growth. Leverage reduction and broad-based order strength support a positive outlook.
Q4 2025 Q4 2025 2026-02-24
Strong 2025 results featured robust revenue and margin growth, driven by protein demand and synergy realization. 2026 guidance calls for 5%-7% revenue growth, margin expansion, and a 29% EPS increase, despite ongoing tariff headwinds and continued integration focus.
Q3 2025 Q3 2025 2025-11-04
Q3 2025 results exceeded expectations with strong revenue, margin, and synergy savings. Raised full-year guidance reflects robust demand, especially in poultry, and successful integration progress. Backlog and cash flow provide strong visibility and support for 2026 growth.
Q2 2025 Q2 2025 2025-08-05
Q2 2025 saw strong revenue, margin, and cash flow, with integration synergies and cross-selling driving results. Full-year guidance was reinstated, with tariffs and FX as key factors; backlog and pipeline remain robust, especially in poultry and recurring revenue.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.